Forte Biosciences Inc. (FBRX)
16.55
1.93 (13.20%)
At close: Jan 15, 2025, 1:43 PM
Company Description
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States.
It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata.
The company is headquartered in Dallas, Texas.
Forte Biosciences Inc.
| Country | United States |
| IPO Date | Apr 13, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Dr. Paul A. Wagner Ph.D. |
Contact Details
Address: 3060 Pegasus Park Drive Dallas, Texas United States | |
| Website | https://www.fortebiorx.com |
Stock Details
| Ticker Symbol | FBRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001419041 |
| CUSIP Number | 34962G109 |
| ISIN Number | US34962G1094 |
| Employer ID | 26-1243872 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Paul A. Wagner Ph.D. | Chief Executive Officer, President & Chairman |
| Antony A. Riley CPA | Chief Financial Officer |
| Christopher Roenfeldt | Chief Operating Officer |
| Dr. Barbara K. Finck M.D. | Chief Medical Clinician & Director |
| Steven Ruhl | Chief Technical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 10, 2025 | SCHEDULE 13G | Filing |
| Jan 02, 2025 | 4 | Filing |
| Jan 02, 2025 | 4 | Filing |
| Dec 31, 2024 | DEF 14A | Filing |
| Dec 20, 2024 | 424B3 | Filing |
| Dec 13, 2024 | S-3 | Filing |
| Dec 06, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Dec 03, 2024 | 8-K | Current Report |
| Nov 22, 2024 | 4 | Filing |
| Nov 20, 2024 | 8-K | Current Report |